Matches in Nanopublications for { <http://rdf.disgenet.org/nanopublications.trig#NP806849.RAkFuh8QlEq5dtXqjbT9hvN-ywmi-lZQ-uHmjAwQ-o8WE130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP806849.RAkFuh8QlEq5dtXqjbT9hvN-ywmi-lZQ-uHmjAwQ-o8WE130_assertion type Assertion NP806849.RAkFuh8QlEq5dtXqjbT9hvN-ywmi-lZQ-uHmjAwQ-o8WE130_head.
- NP806849.RAkFuh8QlEq5dtXqjbT9hvN-ywmi-lZQ-uHmjAwQ-o8WE130_assertion description "[Lastly, the EMX2-high mRNA expressing group had statistically significant better recurrence-free survival (RFS) than the EMX2-low mRNA expression group in patients with adenocarcinoma (P < .001).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP806849.RAkFuh8QlEq5dtXqjbT9hvN-ywmi-lZQ-uHmjAwQ-o8WE130_provenance.
- NP806849.RAkFuh8QlEq5dtXqjbT9hvN-ywmi-lZQ-uHmjAwQ-o8WE130_assertion evidence source_evidence_literature NP806849.RAkFuh8QlEq5dtXqjbT9hvN-ywmi-lZQ-uHmjAwQ-o8WE130_provenance.
- NP806849.RAkFuh8QlEq5dtXqjbT9hvN-ywmi-lZQ-uHmjAwQ-o8WE130_assertion SIO_000772 21726823 NP806849.RAkFuh8QlEq5dtXqjbT9hvN-ywmi-lZQ-uHmjAwQ-o8WE130_provenance.
- NP806849.RAkFuh8QlEq5dtXqjbT9hvN-ywmi-lZQ-uHmjAwQ-o8WE130_assertion wasDerivedFrom befree-20140225 NP806849.RAkFuh8QlEq5dtXqjbT9hvN-ywmi-lZQ-uHmjAwQ-o8WE130_provenance.
- NP806849.RAkFuh8QlEq5dtXqjbT9hvN-ywmi-lZQ-uHmjAwQ-o8WE130_assertion wasGeneratedBy ECO_0000203 NP806849.RAkFuh8QlEq5dtXqjbT9hvN-ywmi-lZQ-uHmjAwQ-o8WE130_provenance.